journal
MENU ▼
Read by QxMD icon Read
search

Current Hematologic Malignancy Reports

journal
https://www.readbyqxmd.com/read/29730710/frailty-in-hematologic-malignancy
#1
REVIEW
Thuy T Koll, Ashley E Rosko
PURPOSE OF REVIEW: Older adults with hematologic malignancy are a growing demographic. Estimating risk of chemotherapy toxicity based on age alone is an unreliable estimate of quality of life, functional capacity, or risk of treatment complications. RECENT FINDINGS: Dedicated geriatric assessment tools can aid the clinician in identifying geriatric syndromes such as frailty, resulting in improved prognostication to decrease morbidity and mortality. Frailty is not synonymous with individual performance status and is dynamic...
May 5, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29725932/light-chain-cast-nephropathy-practical-considerations-in-the-management-of-myeloma-kidney-what-we-know-and-what-the-future-may-hold
#2
REVIEW
Sandhya Manohar, Samih H Nasr, Nelson Leung
PURPOSE OF REVIEW: To update and evaluate the current knowledge on pathogenesis and management of light chain cast nephropathy. Light chain cast nephropathy (LCCN) is the leading cause of acute renal failure in patients with multiple myeloma and is currently recognized as a myeloma defining event. RECENT FINDINGS: The immunoglobulin free light chain plays an integral role in the pathogenesis of LCCN. The level of free light chain (FLC) in the blood and urine is directly associated with the risk of developing LCCN...
May 3, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29713873/post-et-and-post-pv-myelofibrosis-updates-on-a-distinct-prognosis-from-primary-myelofibrosis
#3
REVIEW
Francesco Passamonti, Barbara Mora, Daniela Barraco, Margherita Maffioli
PURPOSE OF REVIEW: The purpose of this review is to help doctors in the management of patients with post-polycythemia (PPV) and post-essential thrombocythemia (PET) myelofibrosis (MF) facing diagnostic criteria, prognostication, and treatment possibilities. RECENT FINDINGS: Diagnostic criteria of primary myelofibrosis (PMF) have been recently updated from the WHO classification. A clear-cut distinction between pre-fibrotic and overt PMF has been done. Concerning PPV and PET MF, the criteria come from 2008...
April 30, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29705880/the-effect-of-psychosocial-interventions-on-outcomes-for-caregivers-of-hematopoietic-cell-transplant-patients
#4
REVIEW
Lauren R Bangerter, Joan M Griffin, Shelby Langer, Bashar Hasan, Wonsun Sunny Kim, M Hassan Murad, Nandita Khera
PURPOSE OF REVIEW: Hematopoietic cell transplant (HCT) patients are required to have a caregiver present for up to 100 days post-transplant. Caregivers provide essential support during HCT but experience immense stress and burden. Increasing research has developed interventions for HCT caregivers. This review systematically evaluates psychosocial interventions for caregivers of HCT patients. RECENT FINDINGS: The search yielded 12 studies (7 efficacy and 5 feasibility studies) enrolling 931 caregivers...
April 28, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29687320/tyrosine-kinase-inhibitors-in-the-treatment-of-chronic-phase-cml-strategies-for-frontline-decision-making
#5
REVIEW
James A Kennedy, Gabriela Hobbs
PURPOSE OF REVIEW: Over the past two decades, the introduction of tyrosine kinase inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four agents currently approved for frontline use in chronic-phase (CP) disease, it follows that treatment decision-making has been rendered more challenging. Here we will review recent advances that help inform the selection of a first-line TKI. RECENT FINDINGS: Extended follow-up of the seminal CML trials has demonstrated the long-term efficacy of TKIs, while also highlighting significant differences in their respective toxicity profiles and potency...
April 23, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29680938/diagnosis-and-novel-approaches-to-the-treatment-of-hypereosinophilic-syndromes
#6
REVIEW
Melanie C Dispenza, Bruce S Bochner
PURPOSE OF REVIEW: Hypereosinophilic syndrome (HES) is characterized by persistent hypereosinophilia associated with end-organ damage. As our understanding of the pathogenesis of various forms of HES broadens, so does our ability to tailor steroid-sparing therapies for each subtype. The purpose of this review is to summarize recent literature related to the etiology, diagnosis, and management of HES. RECENT FINDINGS: Mutations involved in subsets of HES can guide the choice of tyrosine kinase inhibitors beyond just imatinib...
April 21, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29667156/how-we-manage-patients-with-plasmacytomas
#7
REVIEW
Despina Fotiou, Meletios A Dimopoulos, Efstathios Kastritis
PURPOSE OF REVIEW: To discuss the diagnostic approach, treatment options, and future considerations in the management of plasmacytomas, either solitary or in the context of overt multiple myeloma (MM). RECENT FINDINGS: Advanced imaging techniques such as whole-body magnetic resonance imaging and positron emission tomography/computerized tomography are essential for the diagnostic workup of solitary plasmacytomas (SP) to rule out the presence of other disease foci...
April 17, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29644531/splanchnic-vein-thrombosis-in-the-myeloproliferative-neoplasms
#8
REVIEW
Imo J Akpan, Brady Lee Stein
PURPOSE OF REVIEW: To review the epidemiology, diagnostic challenges, pathogenesis, and treatment strategies for patients with myeloproliferative neoplasm-associated splanchnic vein thrombosis. RECENT FINDINGS: The epidemiology of myeloproliferative neoplasm-associated splanchnic vein thrombosis (MPN-SVT) has been well characterized. While typical MPN-associated thrombosis affects older patients and involves the arterial circulation, MPN-SVT mostly impacts younger women...
April 11, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29516333/update-on-the-treatment-of-anaplastic-large-cell-lymphoma
#9
REVIEW
Khoan Vu, Weiyun Ai
PURPOSE OF REVIEW: Given the rarity of anaplastic large cell lymphoma (ALCL), studies evaluating new therapies have typically grouped ALCL together with other peripheral T cell lymphomas (PTCL). Thus, the treatment paradigm for ALCL largely mirrors that of PTCL in general. In this review, we discuss the current standard of care as well as emerging therapies, including antibody-based drugs, in systemic ALCL as well as primary cutaneous and breast implant-associated ALCL. RECENT FINDINGS: High CD30 expression in ALCL has allowed the use of brentuximab vedotin, an anti-CD30 antibody-drug conjugate, in both systemic and primary cutaneous ALCL...
April 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29484578/value-based-care-in-hematopoietic-cell-transplantation-and-cellular-therapy-challenges-and-opportunities
#10
REVIEW
Gunjan L Shah, Navneet Majhail, Nandita Khera, Sergio Giralt
PURPOSE OF REVIEW: Improved tolerability and outcomes after hematopoietic cell transplantation (HCT), along with the availability of alternative donors, have expanded its use. With this growth, and the development of additional cellular therapies, we also aim to increase effectiveness, efficiency, and the quality of the care provided. Fundamentally, the goal of value-based care is to have better health outcomes with streamlined processes, improved patient experience, and lower costs for both the patients and the health care system...
April 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29480432/frontline-therapy-of-cll-evolving-treatment-paradigm
#11
REVIEW
Craig S Boddy, Shuo Ma
PURPOSE OF REVIEW: Chronic lymphocytic leukemia (CLL) has multiple current frontline therapy options, including chemoimmunotherapy (CIT) and most recently, ibrutinib. Here, we review the most recent updates in the frontline treatment of CLL, including updates in CIT, updates in targeted therapies, and ongoing clinical trials. RECENT FINDINGS: Ibrutinib was FDA-approved for the upfront treatment of CLL in 2016 after being studied in older patients and those with 17p deletions or TP53 mutations...
April 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29473123/prognostic-factors-in-the-era-of-targeted-therapies-in-cll
#12
REVIEW
Prajwal Boddu, Alessandra Ferrajoli
PURPOSE OF REVIEW: Chronic lymphocytic leukemia is heterogeneous disease characterized by a variable clinical course that is greatly influenced by various patient and disease characteristics. Over the last two decades, advent of new diagnostic methodologies has led to the identification of several factors of prognostic and predictive relevance. Furthermore, recent advances in next-generation sequencing techniques has identified recurrent novel mutations in NOTCH1, SF3B1, BIRC3, and ATM genes whose role as prognostic and predictive markers is currently being investigated...
April 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29450683/common-adverse-effects-of-novel-therapies-for-multiple-myeloma-mm-and-their-management-strategies
#13
REVIEW
Kristen B McCullough, Miriam A Hobbs, Jithma P Abeykoon, Prashant Kapoor
PURPOSE OF REVIEW: The purpose of this review was to evaluate management strategies for common adverse effects of novel therapies in multiple myeloma (MM), including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and a histone deacetylase inhibitor. RECENT FINDINGS: There are several adverse effects that occur across multiple classes of antimyeloma drugs, including rash, peripheral neuropathy, infusion reactions, and cardiotoxicity, but most can be managed without complete discontinuation of the agent or abandonment of the class...
April 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29442287/recent-developments-in-adolescent-and-young-adult-aya-acute-lymphoblastic-leukemia
#14
REVIEW
Victor M Orellana-Noia, Michael G Douvas
PURPOSE OF REVIEW: Adolescent and Young Adult (AYA) Oncology is a relatively new field encompassing research in the unique pathophysiology, clinical care, and psychosocial issues facing patients between the ages of 15 and 40 with cancer. About 100,000 of the approximately 1.5 million people diagnosed annually with cancer in the USA are in this age range. This chapter will review notable new developments in the care of adolescents and young adults with acute lymphoblastic leukemia (ALL) within the last 3 years...
April 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29423571/novel-therapies-for-older-adults-with-acute-lymphoblastic-leukemia
#15
REVIEW
Nicholas J Short, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi
PURPOSE OF REVIEW: Older adults with acute lymphoblastic leukemia (ALL) have worse survival compared to their younger counterparts. Here, we review the reasons for the poorer outcomes of older patients with ALL and also summarize the current and future therapeutic approaches to ALL in the elderly population. RECENT FINDINGS: The poor outcomes of older adults with ALL are driven largely by lack of tolerance to standard-dose chemotherapy, which leads to unacceptably high rates of myelosuppression-related deaths...
April 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29404834/managing-the-mental-distress-of-the-hematopoietic-stem-cell-transplant-hsct-patient-a-focus-on-delirium
#16
REVIEW
Joseph Bubalo
PURPOSE OF REVIEW: To highlight the breadth and types of mental distress experienced by hematopoietic stem cell transplant (HSCT) patients and highlight the need for better prevention and management of delirium. RECENT FINDINGS: Recent publications highlight additional risks factors which predict for mental distress during the HSCT process. Despite new medications and additional psychological reports, there is little progress in non-pharmacologic or medication therapy in the prevention and treatment of delirium...
April 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29442288/updates-of-peripheral-t-cell-lymphomas-based-on-the-2017-who-classification
#17
REVIEW
Parwiz J Siaghani, Joo Y Song
PURPOSE OF REVIEW: This review will describe and update the readers on the recent changes of the 2017 WHO classification in regard to peripheral T cell lymphomas. RECENT FINDINGS: Significant advances in molecular studies have resulted in revisions of the classification as well as introduction of provisional entities (such as breast implant-associated ALCL, nodal PTCL with TFH phenotype). Major advances in molecular and gene expression profiling have expanded our knowledge of T cell lymphomas, including updates in the diagnostic criteria and sub-classification which will facilitate in improving patient care and research...
February 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29397528/the-future-of-combination-therapies-for-peripheral-t-cell-lymphoma-ptcl
#18
REVIEW
Helen Ma, Ardy Davarifar, Jennifer E Amengual
PURPOSE OF REVIEW: Peripheral T cell lymphoma is a rare heterogeneous group of diseases which are characterized by poor outcomes to treatment and short overall survival. In the past decade, several new therapies targeting T cell biology have been approved in the relapsed setting. These new therapies, such as pralatrexate, romidepsin, belinostat, and brentuximab vedotin, have begun to make their way into practice. Despite these advances, outcomes have not changed dramatically. In recent years, efforts have been made to incorporate these new therapies into combination strategies to treat this challenging disease entity...
February 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29396703/immunologic-milieu-of-mature-t-cell-and-nk-cell-lymphomas-implications-for-therapy
#19
REVIEW
Eric Tse, Yok-Lam Kwong
PURPOSE OF THE REVIEW: T-cells and natural killer (NK) cells share the same ontogeny, and lymphomas derived from them are clinically diverse, occurring in nodal and extranodal sites. In addition to inherent properties of these lymphomas, their microenvironment also impacts on pathogenesis and response to therapy. An understanding of the milieu of T-cell and NK cell lymphomas has important implications on treatment. RECENT FINDINGS: Components of the microenvironment include tumour-associated macrophages (TAM), non-neoplastic T-cells and B-cells, eosinophils, dendritic cells, endothelial cells and blood vessels...
February 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29388008/biomarkers-in-graft-versus-host-disease-from-prediction-and-diagnosis-to-insights-into-complex-graft-host-interactions
#20
REVIEW
Fiona C He, Shernan G Holtan
PURPOSE OF REVIEW: Acute graft versus host disease (aGVHD) is a frequent cause of treatment-related mortality after allogeneic hematopoietic stem cell transplantation (alloHCT), with few effective treatment options beyond systemic steroids. Discovery of biomarkers for aGVHD may provide insight into the pathophysiology of aGVHD and suggest novel mechanisms for treatment. RECENT FINDINGS: We highlight biomarkers within innate immune activation, T-cell-mediated tissue damage, endothelial damage, dysbiosis, and poor wound healing that can be obtained prior to transplant, in the early transplant period, or at the onset of aGVHD...
February 2018: Current Hematologic Malignancy Reports
journal
journal
41232
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"